Nightstar has a phase 3 trial ongoing of NSR-REP1, which uses an AAV vector to deliver the REP1 gene during a surgical procedure, and reported encouraging phase 1/2 results with the therapy in the journal Nature Medicine last year. UK biotech Biogen has bolstered its gene therapy portfolio by acquiring Nightstar -based IRD for around $800m in a cash deal. Biogen will gain Nightstar 's adeno-associated virus treatments for inherited retinal disorders ( IRD ). Nightstar has developed candidates for the blindness-inducing X-linked IRDs choroideremia and retinitis pigmentosa, both of which are potential first -in-class therapies. Biogen has been building its range of gene therapies since forming an alliance with IRD in 2018 .
UK biotech Biogen has bolstered its gene therapy portfolio by acquiring Nightstar -based IRD for around $800m in a cash deal. Biogen will gain Nightstar 's adeno-associated virus treatments for inherited retinal disorders ( IRD ). Nightstar has developed candidates for the blindness-inducing X-linked IRDs choroideremia and retinitis pigmentosa, both of which are potential first -in-class therapies. Biogen has been building its range of gene therapies since forming an alliance with IRD in 2018 .